Merck Expands Singapore Lab with Advanced Biosafety Testing Capabilities
Merck, a leading science and technology company, is expanding its biosafety testing laboratory in Singapore to strengthen services across Asia Pacific. The expansion will add new capabilities for biopharma customers in the region, including BioReliance Cell Line Characterization and GMP next-generation sequencing.
The lab's expansion is part of Merck's global testing expertise, which spans over 75 years. This move supports the industry shift towards molecular methods and animal-free testing.
According to Paolo Carli, Head of Advanced Solutions for the Life Science business of Merck, 'Localizing these BioReliance testing capabilities means our Asia Pacific biopharma customers can accelerate their development timelines, improve operational efficiency, and meet evolving regulatory and sustainability standards.'